https://static.mk.ru/upload/entities/2020/07/15/08/articles/detailPicture/ab/1c/22/85/e970303aecda2b93d310495521983624.jpg

the Association of international pharmaceutical manufacturers , Association of Russian pharmaceutical manufacturers , ROSMEDPROM, “Infarma”, Association of manufacturers of pharmaceuticals and medical products and all-Russian Union of public associations expressed their dissatisfaction with the new requirement to obtain permits for the introduction of medicines that are not labeled. They called the new law “unnecessarily cumbersome, technically difficult, ongoing, corrupt and bureaucratic”.

the Association of Russian pharmaceutical manufacturers were asked to simplify the procedure of entry into circulation of unmarked drugs. According to pharmacists, otherwise, after three or four months in the country can begin interruptions in drug supply. This will lead first to the deficit, and then increase the cost of the medication.

the Letter was sent to Prime Minister Mikhail Mishustin. About it informs “Izvestia”.

the document stated that from July 1, entered into force the rule that to introduce medicines without labeling only upon receipt of permission of the interdepartmental Commission. Pharmacists insist to replace a permit, only a notification of the supply authorities. Previously, this is the norm.

Also, the producers wrote that in the appeal now made of unmarked medications cannot go, since there are no implementing regulations, and the interagency Committee has not yet held a meeting. Thus, 170 declarations on medication without marking waiting for meetings and decisions of the Ministry of health.

Previously, there was a sharp rise in price of analgin. Prices from different manufacturers rose from 25% to 38%. If earlier the average price was 14 rubles, now about 17 rubles. Manufacturers explained such changes increase the cost of imported pharmaceutical substances of which make the drug. The price was affected by the depreciating ruble and stopped the pandemic in the early stages of the pharmaceutical production in India and China. Also dipyrone was removed from the list of essential medicines, for this reason its cost is now not regulated by the state.